---
title: æœƒè­°æ¢è¨-The awesome power of genetic linkage
date: 2025-09-15
authors: ["æˆ´æšç´˜", ""]
commentable: true
categories: [æœƒè­°æ¢è¨]
tags: [Biomedicine,bioinformatics]
isCJKLanguage: true
draft: true
---
<!--more-->
## æœƒè­°æ¨™é¡Œ
ç¦¿é ­
2005 å¹´æ‰¾åˆ°Androgen receptor èˆ‡ç¦¿é ­æœ‰é—œï¼Œä¸”ä½åœ¨X chromosomee ä½†ä¸çŸ¥é“åœ¨å“ªè£¡
æ‰¾äº†95 å®¶æ—ï¼Œgenotyping è¨±å¤šä½åœ¨X chromosome ä¸Šçš„åŸºå› ï¼ŒæŠŠå¯èƒ½æ€§é™ç¸®åˆ°P armï¼Œç•¶ç„¶é€™éƒ½æ˜¯åœ¨GWAS æ™‚ä»£ä¹‹å‰çš„äº‹

## å­Ÿå¾·çˆ¾çš„è±Œè±†


## Violation of independent assortment
1) ç‚ºä»€éº¼æœƒã€Œé•å 9:3:3:1ã€ï¼Ÿâ€”â€”Bateson & Punnett çš„ç”œè±Œè±†ï¼ˆ1905â€“1908ï¼‰
å­Ÿå¾·çˆ¾çš„ç¬¬äºŒå®šå¾‹ï¼ˆç¨ç«‹åˆ†é…ï¼‰é æœŸé›™æ€§ç‹€é›œäº¤çš„ Fâ‚‚ æ¯”ä¾‹æ˜¯ 9:3:3:1ã€‚ä½† William Bateson èˆ‡ Reginald Punnett åœ¨ç”œè±Œè±†åšé›™æ€§ç‹€é›œäº¤ï¼ˆèŠ±è‰²ï¼šç´«/ç´…ï¼›èŠ±ç²‰å½¢ç‹€ï¼šé•·/åœ“ï¼‰æ™‚ï¼Œç™¼ç¾å­ä»£è¡¨å‹é…å°ã€Œéåº¦ä¸€èµ·å‡ºç¾ã€æˆ–ã€Œéåº¦åˆ†é–‹ã€ï¼Œåé›¢ 9:3:3:1ã€‚ä»–å€‘æå‡ºã€Œè€¦åˆï¼ˆcouplingï¼‰ï¼æ’æ–¥ï¼ˆrepulsionï¼‰ã€ä¾†æè¿°é€™ç¨®åŒå‘æˆ–ç›¸æ–¥çš„éºå‚³è¶¨å‹¢ï¼›äº‹å¾Œæ‰è¢«æˆ‘å€‘ç†è§£ç‚ºä½æ–¼åŒä¸€æŸ“è‰²é«”ä¸Šçš„åŸºå› æœƒä¸€èµ·å‚³éï¼ˆé€£é–ï¼‰ï¼Œåªæœ‰åœ¨ç™¼ç”Ÿ**äº’æ›ï¼ˆcrossing overï¼‰**æ™‚æ‰è¢«æ‰“æ•£ã€‚é€™çµ„å¯¦é©—æ˜¯å°ã€Œç¨ç«‹åˆ†é…ã€æœ€æ—©ã€æœ€æ¸…æ¥šçš„ä¾‹å¤–è­‰æ“šä¹‹ä¸€ã€‚

2) å¾ã€Œä¾‹å¤–ã€åˆ°ã€Œç†è«–ã€â€”â€”Morgan çš„é€£é–ç¾¤èˆ‡æ€§é€£é–ï¼ˆ1910â€“1911ï¼‰
åœ¨æœè …ç ”ç©¶ä¸­ï¼ŒThomas H. Morgan ä»¥ç™½çœ¼ç­‰æ€§ç‹€è­‰æ˜åŸºå› ä½åœ¨æŸ“è‰²é«”ä¸Šï¼Œè€Œä¸”åŒä¸€æ¢æŸ“è‰²é«”ä¸Šçš„åŸºå› æœƒå½¢æˆã€Œé€£é–ç¾¤ã€ï¼Œä¸å†æ»¿è¶³å®Œå…¨ç¨ç«‹åˆ†é…ï¼›é€™ç‚ºã€Œé€£é–ã€æä¾›äº†é«”ç³»æ€§çš„æ¦‚å¿µæ¡†æ¶ï¼Œä¹Ÿé‹ªè·¯çµ¦å¾ŒçºŒçš„æ¸¬åœ–å·¥ä½œã€‚
Nature
3) æ€éº¼é‡ã€ŒåŸºå› è·é›¢ã€ï¼Ÿâ€”â€”Sturtevant çš„ç¬¬ä¸€å¼µéºå‚³åœ–ï¼ˆ1913ï¼‰
Morgan çš„å­¸ç”Ÿ Alfred H. Sturtevant éˆå…‰ä¸€ç¾ï¼šäº’æ›é »ç‡èˆ‡å…©åŸºå› åœ¨æŸ“è‰²é«”ä¸Šçš„è·é›¢è¿‘ä¼¼æˆæ­£æ¯”ï¼Œæ–¼æ˜¯åœ¨ 1913 å¹´ç”¨æœè …è³‡æ–™ç•«å‡ºäº†ä¸–ç•Œç¬¬ä¸€å¼µéºå‚³é€£é–åœ–ï¼Œå»ºç«‹äº†ä»¥ 1% é‡çµ„ç‡ = 1 centiMorgan (cM) çš„æ¸¬è·å–®ä½èˆ‡ç·šæ€§æ’åˆ—æ¦‚å¿µï¼Œé€™è®“ã€Œé€£é–ã€å¾ç¾è±¡å­¸èºå‡ç‚ºå¯é‡åŒ–çš„åœ°åœ–å­¸ã€‚

4) ã€Œäº’æ›ã€çœŸçš„æœ‰ç‰©ç†å°æ‡‰å—ï¼Ÿâ€”â€”ç‰ç±³ç¬¬ 9 æŸ“è‰²é«”çš„ç›´æ¥è­‰æ“šï¼ˆ1931ï¼‰
é€£é–èˆ‡äº’æ›è‹¥ç‚ºçœŸï¼ŒåŸºå› å‹çš„é‡çµ„æ‡‰ä¼´éš¨æŸ“è‰²é«”ç‰‡æ®µçš„äº¤æ›ã€‚Harriet Creighton èˆ‡ Barbara McClintock åœ¨ç‰ç±³ï¼ˆZea maysï¼‰ç¬¬ 9 è™ŸæŸ“è‰²é«”ä¸Šï¼Œåˆ©ç”¨ä¸€å°å¯åœ¨é¡¯å¾®é¡ä¸‹è¾¨è­˜çš„**ã€Œæ—‹ç¯€ï¼ˆknobï¼‰ã€èˆ‡æ˜“ä½æ¨™è¨˜**ï¼ŒåŒæ™‚è¿½è¹¤é„°è¿‘åŸºå› ï¼ˆå¦‚ Cã€Wx ç­‰ï¼‰çš„é‡çµ„ï¼šä»–å€‘ç™¼ç¾è¡¨å‹é‡çµ„èˆ‡æŸ“è‰²é«”ç‰‡æ®µç‰©ç†äº’æ›åŒæ™‚ç™¼ç”Ÿï¼Œé¦–æ¬¡æŠŠã€Œéºå‚³é‡çµ„ã€èˆ‡ã€ŒæŸ“è‰²é«”ç‰©ç†äº¤æ›ã€ä¸€ä¸€å°ä¸Šï¼Œæˆç‚ºç¶“å…¸çš„é€£é–/äº’æ›çš„ç´°èƒå­¸è­‰æ“šã€‚åŒå¹´ Curt Stern åœ¨æœè …ä¹Ÿä»¥é«”ç´°èƒåµŒåˆç¾è±¡è£œä¸Šäº†å¹³è¡Œè­‰æ“šã€‚

ä»€éº¼æ˜¯å®¶æ—å‹é€£é–åˆ†æ (family-based linkage analysis)
å®šç¾©
ä¸€ç¨®åˆ©ç”¨ å®¶æ—è³‡æ–™ ä¾†æ‰¾å°‹éºå‚³ç–¾ç—…ç›¸é—œåŸºå› çš„æ–¹æ³•ã€‚
åŸç†æ˜¯ï¼šå¦‚æœæŸæ®µ DNA èˆ‡ç–¾ç—…è¡¨ç¾å‹åœ¨å®¶æ—æˆå“¡ä¸­ä¸€åŒéºå‚³ (co-segregate)ï¼Œå°±è¡¨ç¤ºè©²å€åŸŸå¯èƒ½å«æœ‰è‡´ç—…åŸºå› ã€‚
ğŸ”¬ æ ¸å¿ƒæ¦‚å¿µ
åŸºå› åº§ç›¸é„° â†’ é€£é– (linkage)
åŸºå› ä½åœ¨åŒä¸€æŸ“è‰²é«”ä¸Šã€è·é›¢è¿‘æ™‚ï¼Œä¸å®¹æ˜“è¢«æ¸›æ•¸åˆ†è£‚æ™‚çš„é‡çµ„ (recombination) æ‰“æ–·ã€‚
å› æ­¤æœƒä¸€èµ·å‚³éåˆ°ä¸‹ä¸€ä»£ã€‚
ç”¨æ¨™è¨˜ (genetic markers) è¿½è¹¤
é€éå¾®è¡›æ˜Ÿ (microsatellite) æˆ– SNP æ¨™è¨˜ä¾†è§€å¯Ÿå®¶æ—ä¸­å“ªäº› DNA ç‰‡æ®µèˆ‡ç–¾ç—…ç‹€æ…‹ã€Œä¸€èµ·éºå‚³ã€ã€‚
LOD score (å°æ•¸ä¼¼ç„¶æ¯”)
é€£é–åˆ†æçš„çµ±è¨ˆæ–¹æ³•ï¼ŒLOD â‰¥ 3 é€šå¸¸è¢«èªç‚ºæœ‰é¡¯è‘—é€£é–è­‰æ“šã€‚
ğŸ§ª å¯¦éš›åšæ³•
æ”¶é›†ä¸€å€‹æˆ–å¤šå€‹ å—å½±éŸ¿çš„å®¶æ—ï¼ˆæ‚£ç—…èˆ‡æœªæ‚£ç—…æˆå“¡ï¼‰ã€‚
å»ºç«‹ å®¶ç³»åœ– (pedigree)ï¼Œä¸¦æ¡é›†åŸºå› å‹è³‡æ–™ã€‚
å‡è¨­ä¸€å€‹éºå‚³æ¨¡å¼ï¼ˆå¸¸æŸ“è‰²é«”é¡¯æ€§ / éš±æ€§ã€X è¯é–ç­‰ï¼‰ã€‚
è¨ˆç®—æ¨™è¨˜èˆ‡ç–¾ç—…åŸºå› çš„é‡çµ„ç‡ (Î¸)ã€‚
ç”¨ LOD score åˆ¤æ–·æ¨™è¨˜æ˜¯å¦èˆ‡ç–¾ç—…ä½é»é€£é–ã€‚
ğŸ’¡ èˆ‰ä¾‹
å‡è¨­æœ‰å®¶æ—ï¼š
ç¥–çˆ¶æ¯ â†’ çˆ¸åª½ â†’ å­©å­
è§€å¯Ÿåˆ°æŸå€‹ microsatellite æ¨™è¨˜ æ¯æ¬¡åªè¦å°å­©æ‚£ç—…ï¼Œå¿…å®šå¸¶æœ‰æ¨™è¨˜ Aï¼Œè€Œæ²’ç—…çš„å°å­©å¾ä¸å¸¶ Aã€‚
é€™å°±è¡¨ç¤ºï¼šç–¾ç—…åŸºå› å¾ˆå¯èƒ½è·Ÿé€™å€‹æ¨™è¨˜ã€Œé å¾—å¾ˆè¿‘ã€ï¼Œå› ç‚ºå®ƒå€‘ éš¨è‘—æ¸›æ•¸åˆ†è£‚ä¸€èµ·è¢«éºå‚³ä¸‹ä¾†ã€‚
é€™æ™‚å€™ç ”ç©¶è€…æœƒï¼š
æ‰¾åˆ°é€™å€‹å€åŸŸï¼ˆå¯èƒ½å¹¾ Mb å¤§ï¼‰
å†é€²ä¸€æ­¥åš ç²¾ç´°å®šä½ã€å€™é¸åŸºå› æ¸¬åº â†’ æ‰èƒ½çœŸæ­£æ‰¾å‡ºè‡´ç—…åŸºå› ã€‚
æ—©æœŸæ‰¾å‡º å›Šæ€§çº–ç¶­åŒ– (CFTR)ã€äº¨ä¸é “èˆè¹ˆç—‡ (HTT)ã€BRCA1/2 ä¹³ç™ŒåŸºå›  éƒ½æ˜¯é  family-based linkage analysisã€‚
ç ”ç©¶è€…è¿½è¹¤å¤šä»£å®¶æ—ï¼Œç™¼ç¾æŸäº› DNA æ¨™è¨˜ç¸½æ˜¯èˆ‡ç–¾ç—…å…±åŒéºå‚³ â†’ é–å®šåŸºå› ä½ç½® â†’ å†é€²ä¸€æ­¥ç²¾ç´°å®šä½èˆ‡åŠŸèƒ½ç ”ç©¶ã€‚
ğŸ“Š å„ªç¼ºé»
âœ… å„ªé»
å°æ–¼ é«˜åº¦éºå‚³æ€§ã€å–®åŸºå› ç–¾ç—… ç‰¹åˆ¥æœ‰æ•ˆã€‚
èƒ½åœ¨æ²’æœ‰å¤§è¦æ¨¡ç¾¤é«”è³‡æ–™çš„æƒ…æ³ä¸‹æ‰¾åˆ°å€™é¸åŸºå› å€åŸŸã€‚
âš ï¸ é™åˆ¶
éœ€è¦å¤§å‹å¤šä»£å®¶æ—è³‡æ–™ã€‚
å°å¤šåŸºå› æˆ–è¤‡é›œç–¾ç—…ï¼ˆä¾‹å¦‚ç³–å°¿ç—…ã€å¿ƒè¡€ç®¡ç–¾ç—…ï¼‰æ•ˆæœå·®ã€‚
ç²¾åº¦æœ‰é™ï¼ˆé€šå¸¸å®šä½åˆ°æ•¸ç™¾ kb ~ æ•¸ Mb å€é–“ï¼‰ã€‚

Family based linkage analysis
successful for human mendelian triats but limited for complex traits 
High confidence: genotype --> phenotype (high penetrance, highg effect size)
Low confidence for complex traits 